OTCPK:ELTPPharmaceuticals
Elite Pharmaceuticals (OTCPK:ELTP) Stock Faces Earnings Quality Questions After TTM Profitability Reached
Elite Pharmaceuticals (OTCPK:ELTP) has posted its FY 2026 results with fourth quarter revenue of US$40.7 million and basic EPS of US$0.017, alongside net income, excluding extra items, of US$18.5 million. Over the past year, the company has seen total revenue across reported periods range from US$14.4 million to US$40.7 million per quarter, while quarterly basic EPS has moved between a loss of US$0.011 and a profit of US$0.017. This gives investors a clearer view of how the top line and per...